Roche Holding AG Company Profile (OTCMKTS:RHHBY)

About Roche Holding AG

Roche Holding AG logoRoche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: RHHBY
  • CUSIP:
Key Metrics:
  • Previous Close: $31.54
  • 50 Day Moving Average: $31.28
  • 200 Day Moving Average: $31.60
  • 52-Week Range: $6,817,301,000.00 - $29.89
  • Trailing P/E Ratio: 23.27
  • Foreward P/E Ratio: 15.61
  • P/E Growth: 2.15
  • Market Cap: $215.02B
  • Outstanding Shares: 6,817,301,000
  • Beta: 0.71
  • Debt-to-Equity Ratio: 0.73%
  • Current Ratio: 1.19%
  • Quick Ratio: 0.86%
Additional Links:
Companies Related to Roche Holding AG:

Analyst Ratings

Consensus Ratings for Roche Holding AG (OTCMKTS:RHHBY) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $177.50

Analysts' Ratings History for Roche Holding AG (OTCMKTS:RHHBY)
DateFirmActionRatingPrice TargetDetails
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
1/22/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details
10/20/2015Cowen and CompanyDowngradeOutperform -> Market Perform$42.00 -> $35.00View Rating Details
10/13/2015Credit Suisse Group AGReiterated RatingOutperform$320.00View Rating Details
7/20/2015Baader BankUpgradeBuyView Rating Details
6/25/2015HSBCInitiated CoverageBuyView Rating Details
5/22/2015Erste GroupInitiated CoverageBuyView Rating Details
3/13/2015Liberum CapitalDowngradeHoldView Rating Details
1/28/2015Bryan, Garnier & CoUpgradeBuyView Rating Details
11/25/2014BNP ParibasInitiated CoverageOutperformView Rating Details
11/13/2014Kepler Capital MarketsDowngradeHoldView Rating Details
(Data available from 9/25/2014 forward)


Earnings History for Roche Holding AG (OTCMKTS:RHHBY)
No earnings announcements for this company have been tracked by


Earnings Estimates for Roche Holding AG (OTCMKTS:RHHBY)
Current Year EPS Consensus Estimate: $1.88 EPS
Next Year EPS Consensus Estimate: $2.02 EPS


Dividend History for Roche Holding AG (OTCMKTS:RHHBY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Roche Holding AG (OTCMKTS:RHHBY)
No insider trades for this company have been tracked by


Latest Headlines for Roche Holding AG (OTCMKTS:RHHBY)
News IconPuma Biotechnology Inc 28.1% Potential Upside Now Implied by Stifel (OTCMKTS:RHHBY) - September 24 at 8:03 AM logoBioLineRx Begins Trial on BL-8040/ Keytruda Combination - Yahoo Finance (OTCMKTS:RHHBY) - September 22 at 11:50 AM logoHow Roche’s Valuation Compares to Its Peers (OTCMKTS:RHHBY) - September 22 at 11:50 AM logoAllergan to Buy Tobira Therapeutics in $1.7 Billion Deal - Wall Street Journal (OTCMKTS:RHHBY) - September 20 at 12:21 PM logoRoche Sees Soaring Revenue from Its Bladder Cancer Treatment (OTCMKTS:RHHBY) - September 16 at 10:37 AM logoRoche Ocrevus Positive in Phase III Multiple Sclerosis Trials (OTCMKTS:RHHBY) - September 15 at 10:39 AM logoNo Dog Days For Moat Investors - Seeking Alpha (OTCMKTS:RHHBY) - September 12 at 6:40 PM logo2 Hot Biotech Stocks Trading at Bargain Prices Right Now (OTCMKTS:RHHBY) - September 8 at 6:46 PM logoWhat Are the Possible Threats to Revlimid? (OTCMKTS:RHHBY) - September 8 at 10:53 AM logoRoche Immuno-oncology Drug Tecentriq Positive in Phase III (OTCMKTS:RHHBY) - September 1 at 10:12 AM logo2:45 am Roche Hldg's Zika PCR test receives Emergency Use Authorization from the FDA (OTCMKTS:RHHBY) - August 30 at 10:22 AM logoFDA Advises Zika Test for All U.S. Blood: Will Hologic Gain? (OTCMKTS:RHHBY) - August 29 at 11:41 AM
News IconRoche Receives US FDA Emergency Use Authorization for Zika Test (OTCMKTS:RHHBY) - August 29 at 11:41 AM logoRoche (RHHBY) Stock Higher, FDA Gives Emergency Approval for Zika Test (OTCMKTS:RHHBY) - August 29 at 11:41 AM logoWhat's the Sector Composition of the Fidelity Advisor Overseas Fund? - Market Realist (OTCMKTS:RHHBY) - August 27 at 6:21 PM logoWhat's the Sector Composition of the MFS International Growth Fund? - Market Realist (OTCMKTS:RHHBY) - August 27 at 6:21 PM logoLet's look at what has contributed to the fund's performance YTD in 2016. - Market Realist (OTCMKTS:RHHBY) - August 27 at 6:21 PM logoWhat's the Sector Composition of the FNGAX? - Market Realist (OTCMKTS:RHHBY) - August 26 at 6:48 PM logoGermany's Merck Builds Up Non-Drug Businesses - Wall Street Journal (OTCMKTS:RHHBY) - August 26 at 10:04 AM
News IconShares Fall as Health-Care Sector Loses Ground -- Update (OTCMKTS:RHHBY) - August 25 at 12:13 PM logoRoche : launches innovative Accu-Chek Guide blood glucose monitoring system, which makes every step of testing easy (OTCMKTS:RHHBY) - August 23 at 7:13 PM logoRoche : launches innovative Accu-Chek® Guide blood glucose monitoring system, that makes every step of testing easy (OTCMKTS:RHHBY) - August 23 at 11:39 AM logoInnovative Diagnostic and Therapeutic Products Seen at Roche (OTCMKTS:RHHBY) - August 22 at 11:43 AM logoCerulean (CERU) Kidney Cancer Drug Disappoints in Phase II (OTCMKTS:RHHBY) - August 18 at 10:08 AM logoROCHE HOLDING LTD /FI Financials (OTCMKTS:RHHBY) - August 16 at 7:13 PM logoPomalyst Continues to Witness Strong Global Demand in 2016 - Market Realist (OTCMKTS:RHHBY) - August 16 at 10:26 AM logoEpizyme Doses First Patient in Phase II Mesothelioma Study (OTCMKTS:RHHBY) - August 15 at 9:18 AM logoHow Did Valeant’s Segments Perform in 2Q16? (OTCMKTS:RHHBY) - August 12 at 10:19 AM logoSamsung BioLogics Aims to Raise Up to $2.5 Billion From IPO - Wall Street Journal (OTCMKTS:RHHBY) - August 11 at 7:38 PM logoEpizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise (OTCMKTS:RHHBY) - August 9 at 10:22 AM logoBlood Banks Step Up Efforts Against Zika Contamination - Wall Street Journal (OTCMKTS:RHHBY) - August 4 at 7:35 PM logoBiogen Draws Takeover Interest from Rival Drugmakers - Wall Street Journal (OTCMKTS:RHHBY) - August 2 at 7:29 PM logoWill ImmunoGen (IMGN) Disappoint Again on Q4 Earnings? (OTCMKTS:RHHBY) - August 2 at 7:29 PM logoRoche introduces virtual reality theater at AACC 2016 Clinical Lab Expo to give lab professionals firsthand glimpse of connected lab of the future (OTCMKTS:RHHBY) - August 2 at 12:06 PM logoRoche launches new target enrichment systems for genetic and translational research (OTCMKTS:RHHBY) - August 2 at 12:06 PM logoStrong Growth for Soliris in 2Q16 (OTCMKTS:RHHBY) - August 1 at 11:08 AM logoExperimental Alzheimer's Drug Fails in Clinical Trial - Wall Street Journal (OTCMKTS:RHHBY) - July 29 at 10:08 AM logoRoche : emicizumab continued to show promising safety and efficacy profile in long-term study in people with severe haemophilia A (OTCMKTS:RHHBY) - July 28 at 10:22 AM logoA Look at Roche’s Potential Revenue Drivers (OTCMKTS:RHHBY) - July 26 at 9:05 AM logoAn Investing Overview of the Multiple Sclerosis Market (OTCMKTS:RHHBY) - July 26 at 8:21 AM logoRoche (RHHBY) Misses on Q2 Revenues, New Launches in Focus (OTCMKTS:RHHBY) - July 25 at 6:32 PM logoUnderstanding the Performance of Roche’s Key Drugs (OTCMKTS:RHHBY) - July 25 at 11:06 AM logoSales Performance Analysis of Roche’s Pharmaceuticals Division (OTCMKTS:RHHBY) - July 25 at 9:07 AM logoDissecting Roche’s Performance across Its Segments (OTCMKTS:RHHBY) - July 22 at 6:01 PM logoReasons behind Roche’s Better-than-Expected 2Q16 Performance (OTCMKTS:RHHBY) - July 22 at 6:01 PM logoAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin - Wall Street Journal (OTCMKTS:RHHBY) - July 21 at 7:27 PM logoRoche Sales Rise on Cancer Drugs - Wall Street Journal (OTCMKTS:RHHBY) - July 21 at 7:27 PM logo[$$] Roche says UK faces losing lead in medical research after Brexit (OTCMKTS:RHHBY) - July 21 at 6:35 AM logoRoche CEO Confident Business Will Succeed Despite Turmoil (OTCMKTS:RHHBY) - July 21 at 4:38 AM
News IconAre Analysts Bearish Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) After Last Week? - Consumer Eagle (OTCMKTS:RHHBY) - July 19 at 8:06 AM


Roche Holding AG (OTCMKTS:RHHBY) Chart for Sunday, September, 25, 2016

Last Updated on 9/25/2016 by Staff